Surveillance of AFP
Surveillance of AFP
Surveillance of AFP
• Current Epidemiology
• Impact & future strategy in regard to current
epidemiology
• What is AFP Surveillance
• Why AFP Surveillance
• Role of Medical Officer & DIO in AFP Surveillance
•
1|
WHO
Current Scenario
2|
WHO
Polio type 1
3|
WHO
Polio type 3
4|
Impact of polio eradication initiative
Impact of Polio Eradication WHO
Strategies
Time from 1st NID to last indigenous virus*
The average time to
interrupt indigenous wild
poliovirus has been 2.5
years
Remaining endemic
countries as of 2002
2006
10 of 13 re-infected
countries are again polio-
free.
2007
circulating imported virus,
2006
Continuing
7
Newoutbreak
importation,
WHO
Program Follow-up
9|
WHO
Polio type 1
Uttar Pradesh (UP)
10
WHO
In 2007, immunity in UP rose above the levels that
stopped type 1 in the Rest of India
Summary: WPV1 in UP
2007-2008
• West UP: Until the Badaun case in May, 20 of 24
districts were free since Nov 2006, all districts free
since August 2007 – longest period ever
• All UP:
– Highest levels of immunity to WPV1
– Transmission likely stopped in late 2007
– Recent 7 cases in and adjacent to Badaun district
following importation from Bihar
WPV1 – 2007
WPV1 – 2008
WPV1 – Sewage 2008
12 of the 13 WPV1 isolates in 2008 are linked to WPV1
circulating in Bihar
13
WHO
Polio type 3
15
P3 polio cases, India
2005
2004 2006
##
# #
#####
#
##
####
# ##
#
#
# ##
#
##
##
#
#
# #
#
4
7 28
2007 2008*
# #
##
##
##
#
##
##
#
##
##
##
#
##
##
###
##
##
#
#
#
##
#
#
##
#
##
###
##
### #
##
#
##
#
#
#
##
#
#### # #
#
#
#
#
#
##
#
#
##
#
#
##
##
####
# ##
#
#
###
##
#
# #
##
##
#
#
##
##
#
##
#
#
#
## #
## # #
##
# ##
####
#
#
#
#
#
#
#
##
#
# # #
#
## #
###
### ##
##
##
# #
## ## #
## #
#
#### ####
# # # ## # #
#
########
##
## # #### #
# #
# # ###
#
###
###
#
#
#
#
#
#
##
#
## ##
#
#
#
#
#
#
#
#
#
#
#
#
###
## #
## #
#
## #
## #####
###
# #
# # # # # #
# #
#
#
#
#
#
#
#
#
#
#
#
#
#
#
#
#
##
#
#
#
#
#
#
#
#
#
##
#
#
#
#
##
##
#
#
#
#
#
#
#
#
#
#
#
#
#
#
#
#
#
#
# #
## ##
# ##
#
#
#
#
##
#
##
#
##
##
##
#
#
#
#
#
#
#
##
#
#
#
#
#
##
#
#
#
#
#
#
#
#
#
#
## ##
# ### # # # #
###
# # #
#
## ##
#
##
#
#
#
#
#
###
# #
##
#
#
##
#
#
##
#
# #
#
#
#
#
#
#
###
# ##
#
##
#
###
##
#
### ##
# ##
#
## ###
#
#
#
##
#
#
##
#
###
##
##
# # ##
# ##
#
#
#
#
#
#
#
#
#
#
#
##
#
#
#
#
#
##
#
#
#
##
####
# ##
# # # # ##
# # #
#
#
# ### #
###
##
##
###
##
##
#
##
#
##
#
##
#
##
#
###
#
# #
# ###
# # ###
##
##
##
##
##
##
#####
## ###
# # #
# #
# # ##
#
#
794
346
WHO
Summary WPV3
• WPV3 outbreaks have declined
Poliovirus
• Belongs to genus:
Enterovirus, family
Picornaviridae.
• Made up of single
strand of RNA
• Three well defined
serotypes: 1,2 and 3
– all types cause
paralysis
– Type 1 most
frequent
19
WHO
20
Assumptions About Polio WHO
• Highly contagious
• Vaccine-induced immunity short-lived
• High vaccination coverage needed to meet herd-
immunity threshold
21
WHO
22
WHO
Enhanced Surveillance
23
WHO
24
WHO
25
WHO
26
WHO
27
WHO
28
WHO
Chain of Transmission
Source Index
Case
29
Sub clinical
WHO
Herd Immunity
Sustained
transmission
Transmission
terminated
30
WHO
31
WHO
32
Why AFP cases must be WHO
reported immediately
collection of stool specimens should be
within 14 days of disease onset
case investigation should begin before
the patient leaves hospital/village
response activities require planning and
must begin soon
33
WHO
or
Stool Shipment to Lab
Special tests for expert Group Stool collection>14 days
34
WHO
Role of Clinicians
in
AFP Surveillance
35
WHO
Acute Weakness/paresis/paralysis
• Myopathic
36
WHO
Pattern of weakness
Sign UMN LMN Myopathic
• Atrophy - +++ +
• Fasciculation's - +++ -
• Babinski’s sign + - -
37
WHO
38
WHO
Clinical dilemma…..
• Polio Vs other causes of paralysis
– Issue resolved by having surveillance of all cases of
flaccid paralysis
• AFP Vs Borderline AFP
– How to resolve it?
Solution: Investigate borderline cases too!!
• Include every case, if currently the child has flaccid
paralysis or if there is history of flaccid paralysis
• If in doubt, include the case…
This will help in increasing the Surveillance sensitivity
39
WHO
Transverse Radiculapathies
Myelitis
Traumatic neuritis Other enteroviruses
40
WHO
Surveillance
sensitivity is
True AFP cases
adequate
Polio cases enough to
Non-AFP cases detect 90% polio
cases
Borderline/ambiguous AFP cases
41
WHO
When transmission is very low…..
If stool is Surveillance
collected sensitivity is
from not good
borderline enough &
or detects only
ambiguous 50% polio
cases… cases
Sensitivity
increases
and leads
True AFP cases to nearly
Polio cases 100%
detection
Non-AFP cases of polio
Borderline/ambiguous AFP cases cases
42
Virological AFP Case Classification Scheme WHO
Compatible
Expert
Review
No Residual
Discard
No Wild Polio Weakness
Virus
43
What is Expected from you… WHO
44
AFP Reporting network WHO
45
WHO
Surveillance Indicators
46
Surveillance Indicators for WHO
Polio
• Indicator
48
WHO
Issues
• Reporting of cases
• Interest in national health program
• Completeness of CIF
• Active case search in community , Reporting site
• Clinical examination of case
• Feed back to patients relatives
49
Role and responsibility
WHO
Summary
• AFP is a Public Health Emergency.
• AFP is a notifiable disease as per GoI guidelines
• AFP reporting helps Patient, Clinician & Nation
• PE programme is based on quality AFP Surveillance &
Your role is critical.
53
WHO
Europe
Last case
Turkey 1998 4
54
NPSP - WHO
Thank you…